A negative anti-amyloid drug trial results show that crenezumab is not superior to placebo for genetically high-risk Alzheimer’s patients
Top-line study results were released earlier this year. However, the researchers presented additional findings and perspectives at the Alzheimer’s Association International Conference 2022. The investigational anti-amyloid monoclonal antibody crenezumab (Genentech) is not superior to a placebo for change in cognition, brain imaging, or biomarker outcomes in individuals who are at genetically high risk for Alzheimer’s disease (AD), […]
